Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Position Decreased by Global Retirement Partners LLC

Global Retirement Partners LLC lessened its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) by 13.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,917 shares of the company’s stock after selling 740 shares during the period. Global Retirement Partners LLC’s holdings in Akero Therapeutics were worth $137,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Creative Planning bought a new position in Akero Therapeutics in the 3rd quarter worth about $371,000. Mirae Asset Global Investments Co. Ltd. grew its position in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after purchasing an additional 446 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Akero Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,354 shares of the company’s stock worth $383,000 after purchasing an additional 5,230 shares during the last quarter. Emerald Advisers LLC grew its position in Akero Therapeutics by 1.8% in the 3rd quarter. Emerald Advisers LLC now owns 524,427 shares of the company’s stock worth $15,046,000 after purchasing an additional 9,175 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new position in Akero Therapeutics in the 3rd quarter worth about $211,000.

Insider Activity at Akero Therapeutics

In other Akero Therapeutics news, COO Jonathan Young sold 10,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $32.13, for a total value of $321,300.00. Following the completion of the sale, the chief operating officer now owns 206,286 shares in the company, valued at $6,627,969.18. This represents a 4.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Andrew Cheng sold 25,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $32.09, for a total transaction of $802,250.00. Following the completion of the sale, the chief executive officer now owns 605,417 shares of the company’s stock, valued at approximately $19,427,831.53. The trade was a 3.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 208,992 shares of company stock worth $9,633,413. 7.94% of the stock is owned by corporate insiders.

Akero Therapeutics Stock Up 0.4 %

Shares of NASDAQ:AKRO opened at $47.67 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The company has a market cap of $3.33 billion, a PE ratio of -12.71 and a beta of -0.11. Akero Therapeutics, Inc. has a 52 week low of $17.86 and a 52 week high of $58.40. The firm has a 50 day simple moving average of $38.14 and a 200 day simple moving average of $32.23.

Wall Street Analysts Forecast Growth

AKRO has been the subject of several recent analyst reports. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $35.00 to $63.00 in a report on Thursday, January 30th. HC Wainwright increased their price objective on shares of Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a report on Monday, January 27th. Morgan Stanley increased their price objective on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. UBS Group increased their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a report on Friday, January 31st. Finally, Canaccord Genuity Group increased their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $75.86.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.